Life Sciences

Congress should ratify the proposed USMCA and in particular support its provision requiring 10 years of data protection for biologic drugs. The result will be a more competitive U.S. biopharmaceutical industry, more high-paying American jobs and more incentives to produce new cures.
Life Sciences
Check a box to narrow search for individual content items that cover numerous issues.
November 26, 2019
Congress should ratify the proposed USMCA and in particular support its provision requiring 10 years of data protection for biologic drugs. The result will be a more competitive U.S. biopharmaceutical industry, more high-paying American jobs and more incentives to produce new cures.
November 25, 2019
Proponents of capping drug prices often dismiss concerns about the impact on pharmaceutical R&D by pointing to the fact that drug prices are much lower internationally than in the United States. But this reasoning fails to consider that price restrictions in other countries have made pharmaceutical companies disproportionately reliant on revenue from the United States.
October 21, 2019
In response to increased public pressure, both Congress and the Trump Administration have recently promoted efforts to reduce the price of prescription drugs in the United States. Several other countries have already imposed measures of their own.
September 24, 2019
Val Giddings' presentation to the Breakthrough Institute at Ecomodernism 2019 explores research to improve the efficiency of photosynthesis and what this means for climate mitigation and the global economy.
September 18, 2019
Policymakers should recognize that the potential of data-driven drug development is crucial to the well-being of Americans as well as U.S. competitiveness, and develop policies to accelerate this transformation.
September 9, 2019
Academic studies consistently show that a reduction in current drug revenues leads to a fall in future research and the number of new drug discoveries.
August 12, 2019
China is challenging the United States for market share and jobs in one of the highest value-added, most innovation-intensive industries—and the risks extend not just to the U.S. economy, but to global biopharma innovation.
August 6, 2019
As Eline Chivot writes in Health Europa, EU policymakers should call for France and Germany to lift their bans on direct-to-consumer genetic testing and instead harmonize laws to create a single market.
June 20, 2019
ITIF hosted an expert panel discussion on impact drug-price controls have and what effect, if any, mandated drug-price reductions would have on biopharmaceutical innovation and U.S. industry competitiveness.
June 6, 2019
The United States must stand up for innovation in the debate over the U.S.-Mexico-Canada Agreement (USMCA), ITIF's Stephen Ezell, the Macdonald-Laurier Institute's Richard Owens, and Fundacion Idea's Alberto Saracho write in The Hill.

Pages